AstraZeneca PLC (AZN)
Pre-Market:
| Previous Close | 70.85 |
| Open | 71.41 |
| Bid | 61.36 x 100 |
| Ask | 71.24 x 600 |
| Day's Range | 70.68 - 71.47 |
| 52 Week Range | 60.47 - 75.75 |
| Volume | |
| Avg. Volume | 6,213,475 |
| Market Cap | 220.751B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 37.28 |
| EPS (TTM) | 1.91 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.45 (2.04%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | 81.81 |
- Yahoo Finance Video
Alphabet, Microsoft, Southwest earnings: What to watch
Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
UPDATE 2-AstraZeneca trounces first-quarter estimates as resilient demand fuels growth
AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, underpinning strong demand for its blockbuster drugs and steady sales from partnered medicines. Oncology, the Anglo-Swedish drugmaker's top business, clocked a 26% jump in first-quarter sales to $5.12 billion. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes.
ReutersAstraZeneca leaps after smashing first quarter forecasts
(Reuters) -AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from partnered medicines, and sending its shares up over 5%. CEO Pascal Soriot has rebuilt the company's pipeline of new drugs since taking the helm more than a decade ago, to make blockbusters such as lung cancer drug Tagrisso, leukaemia drug Calquence and Farxiga for diabetes. Combined revenue from partnered medicines, such as breast cancer therapy Enhertu with Daiichi Sankyo and asthma medicine Tezspire with Amgen, jumped more than 60% in the quarter, bolstering overall growth.
